Artiva Biotherapeutics, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Artiva Biotherapeutics, Inc. Common Stock generated cash of -$47,430,000, which is more than the previous year. Cash used in financing activities reached the amount of $24,391,000 last year. Net change in cash is therefore -$49,014,000.
Cash Flow
| 2022 | -50.82M | -6.29M | -1.26M |
|---|---|---|---|
| 2023 | -47.43M | -25.97M | 24.39M |
ARTV Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 102.77M | 161.16M |
Operating activities | ||
Net income | -28.72M | -58.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 2.26M | 1.15M |
Stock-based compensation expense | 7.05M | 6.58M |
| Deferred income tax benefit | 7.05M | 6.58M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | -510K | -57K |
Inventories | 0 | 0 |
Accounts payable | -408K | 190K |
Cash generated by operating activities | -47.43M | -50.82M |
Investing activities | ||
Purchases Of Investments | -49.51M | 0 |
Investments In Property Plant And Equipment | -3.25M | -6.29M |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -25.97M | -6.29M |
Financing activities | ||
Common Stock Issued | 0 | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | -12K | -5K |
Repayments of term debt | 0 | 0 |
Cash used in financing activities | 24.39M | -1.26M |
Net Change In Cash | -49.01M | -58.39M |
Cash at end of period | 53.76M | 102.77M |